Objective: Determine if maximum doses of rosuvastatin are safe in patients infected with
hepatitis C and if the so called pleiotropic effects of rosuvastatin cause a decrease in the
HCV viral load.
Primary study parameters: 1. to which extend causes rosuvastatin serious side effects like
rhabdomyolysis and hepatotoxicity in patients chronically infected with hepatitis C? 2. does
treatment with rosuvastatin in HCV infected patients lead to lower HCV-RNA viral load? 3. Is
a decrease in LDL correlated to a decrease in HCV-RNA load?